BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37538790)

  • 1. Clinicopathological characteristics and prognostic analysis of breast cancer with a hormone receptor status of ER(-)/PR(+).
    Wang X; Xue Y
    Front Endocrinol (Lausanne); 2023; 14():1193592. PubMed ID: 37538790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of progesterone receptor on metastasis and prognosis in breast cancer patients with negative HER-2.
    Xiao Y; Li J; Wu Z; Zhang X; Ming J
    Gland Surg; 2022 Jan; 11(1):77-90. PubMed ID: 35242671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological features and prognosis of male breast cancer.
    Wang X; Liu S; Xue Y
    J Int Med Res; 2021 Oct; 49(10):3000605211049977. PubMed ID: 34713754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features.
    Senel F
    Indian J Pathol Microbiol; 2021; 64(4):671-676. PubMed ID: 34673584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
    Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
    Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term prognostic effect of hormone receptor subtype on breast cancer.
    Hwang KT; Kim J; Jung J; Kim BH; Park JH; Jeon SY; Hwang KR; Roh EY; Park JH; Kim SJ
    Breast Cancer Res Treat; 2020 Jan; 179(1):139-151. PubMed ID: 31595365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
    Wei JL; Zhang JX; Fu DY
    World J Surg Oncol; 2018 Dec; 16(1):236. PubMed ID: 30558615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
    Dunnwald LK; Rossing MA; Li CI
    Breast Cancer Res; 2007; 9(1):R6. PubMed ID: 17239243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
    Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens MR
    J Clin Pathol; 2005 Jun; 58(6):611-6. PubMed ID: 15917412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.
    Chuthapisith S; Permsapaya W; Warnnissorn M; Akewanlop C; Sirivatanauksorn V; Prasarttong Osoth P
    Asian Pac J Cancer Prev; 2012; 13(2):459-62. PubMed ID: 22524806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
    Fan Y; Wang Y; He L; Imani S; Wen Q
    ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of risk factors of axillary lymph node metastasis and prognosis in T1 breast cancer: a large-scale retrospective study based on the SEER database].
    Wang WY; Meng XZ; Li N; Zeng HM; Liu JX; Feng KX; Wang PL; Wang X
    Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(27):2152-2158. PubMed ID: 34275251
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
    Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
    J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid receptor status and its clinicopathological correlation in post-menopausal breast cancer patients of Kumaon region of Uttarakhand.
    Shahi KS; Bhandari G; Singh A
    J Cancer Res Ther; 2011; 7(1):19-22. PubMed ID: 21546737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.